Emergent BioSolutions Inc. (EBS): Long-Term Debt
$589.70M
As of 2025-12-31
$589.70M
As of 2026-06-30
-25.3%
3-year compound annual growth
-7.8%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $589.70M | -15.8% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $700.00M | -19.4% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $868.40M | -38.6% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $1.41B | +66.4% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $849.60M | -4.1% | 2023-12-11, Balance as of period end |
| 2020-12-31 | $885.50M | +7.7% | 2022-02-25, Balance as of period end |
| 2019-12-31 | $822.50M | +1.7% | 2021-02-19, Balance as of period end |
| 2018-12-31 | $808.80M | n/m | 2020-02-25, Balance as of period end |
| 2017-12-31 | $13.60M | n/a | 2019-02-22, Balance as of period end |
| No annual figure between 2013-12-31 and 2017-12-31. | |||
| 2013-12-31 | $62.00M | -1.2% | 2014-03-10, Balance as of period end |
| 2012-12-31 | $62.77M | +5.6% | 2014-03-10, Balance as of period end |
| 2011-12-31 | $59.45M | n/a | 2013-03-08, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $589.70M | -15.8% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $372.19M | -36.4% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $163.66M | -8.7% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $343.97M | -21.3% |
| Insmed Inc (INSM) | 2025-12-31 | $546.77M | -51.3% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $1.81B | +44.6% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $339.88M | +189.1% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $93.16M | +12.5% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $993.95M | +0.2% |
Compare EBS, PCRX, HRMY, OPK side by side · Screen every company in Pharmaceutical Preparations ↗